{"id":"W4413786495","doi":"10.1093/bjd/ljaf327","title":"SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement","year":2025,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Probity Medical Research; Dalhousie University; Innovaderm (Canada)","funders":"Johnson and Johnson; Dermira; Celgene; Teva Pharmaceutical Industries; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Intertriginous; Body surface area; Placebo; Psoriasis; Clinical endpoint; Psoriasis Area and Severity Index; Randomized controlled trial; Internal medicine; Dermatology; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002322294,0.001045118,0.001312633,0.0002916452,0.000405258,0.0009384527,0.0007451398,0.001544368,0.009919311],"category_scores_gemma":[0.001731056,0.0004319534,0.001085012,0.0002554228,0.0007522072,0.0007655731,0.0003149291,0.002697592,0.001557766],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005806288,"about_ca_system_score_gemma":0.001289845,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000350408,"about_ca_topic_score_gemma":0.001037165,"domain_scores_codex":[0.9996067,0.0002036088,0.00002574886,0.00006371999,0.00004796022,0.00005237016],"domain_scores_gemma":[0.9992571,0.0001441738,0.0002128983,0.00005393672,0.00009682932,0.0002350162],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8647882,0.0193727,0.002671332,0.002239043,0.000994814,0.0001391274,0.0002235161,0.0009887193,0.0296913,0.0005213425,0.01244668,0.06592319],"study_design_scores_gemma":[0.8593332,0.1252368,0.00660858,0.0001544087,0.0003524509,0.0001716649,0.00003265501,0.0005051414,0.002179859,0.0003252807,0.005081165,0.00001874032],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9591798,0.01027392,0.002035294,0.002256793,0.0004280491,0.01118376,0.005371015,0.000464658,0.008806718],"genre_scores_gemma":[0.9595107,0.004703044,0.005341663,0.002584366,0.0003712243,0.01271039,0.00437146,0.00009469131,0.01031252],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009919311,"threshold_uncertainty_score":0.0331834,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03858534808544913,"score_gpt":0.3233213397615486,"score_spread":0.2847359916760995,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}